Empagliflozin Therapy and Insulin Resistance-associated Disorders: Effects and Promises Beyond a Diabetic State

Overview

Journal Arch Med Sci Atheroscler Dis

Date 2021 May 24

PMID 34027215

Citations 5

Authors

Georgios S Papaetis

Affiliations

Soon will be listed here.

Abstract

Empagliflozin is a SGLT2 inhibitor that has shown remarkable cardiovascular and renal activities in patients with type 2 diabetes (T2D). Preclinical and clinical studies of empagliflozin in T2D population have demonstrated significant improvements in body weight, waist circumference, insulin sensitivity, and blood pressure - effects beyond its antihyperglycaemic control. Moreover, several studies suggested that this drug possesses significant anti-inflammatory and antioxidative stress properties. This paper explores extensively the main preclinical and clinical evidence of empagliflozin administration in insulin resistance-related disorders beyond a diabetic state. It also discusses its future perspectives, as a therapeutic approach, in this high cardiovascular-risk population.

Citing Articles

The Impact of Sodium-Glucose Co-Transporter-2 Inhibition on Insulin Resistance and Inflammation in Patients with Type 2 Diabetes: A Retrospective Study.

Iordan L, Lazar S, Timar R, Popescu S, Sorescu T, Albai O Medicina (Kaunas). 2025; 61(2).

PMID: 40005325 PMC: 11857714. DOI: 10.3390/medicina61020209.

SGLT2 inhibitors, intrarenal hypoxia and the diabetic kidney: insights into pathophysiological concepts and current evidence.

Papaetis G Arch Med Sci Atheroscler Dis. 2024; 8:e155-e168.

PMID: 38283924 PMC: 10811536. DOI: 10.5114/amsad/176658.

GLP-1 receptor agonists, SGLT-2 inhibitors, and obstructive sleep apnoea: can new allies face an old enemy?.

Papaetis G Arch Med Sci Atheroscler Dis. 2023; 8:e19-e34.

PMID: 37153372 PMC: 10161791. DOI: 10.5114/amsad/161170.

Empagliflozin Ameliorates Progression From Prediabetes to Diabetes and Improves Hepatic Lipid Metabolism: A Systematic Review.

Hossain M, Khan N, Rahman A, Chowdhury M, Bari S, Khan M Cureus. 2022; 14(8):e28367.

PMID: 36168335 PMC: 9506669. DOI: 10.7759/cureus.28367.

Pioglitazone in diabetic kidney disease: forgotten but not gone.

Papaetis G Arch Med Sci Atheroscler Dis. 2022; 7:e78-e93.

PMID: 36158067 PMC: 9487837. DOI: 10.5114/amsad/151046.

References

Kanat M, Winnier D, Norton L, Arar N, Jenkinson C, DeFronzo R . The relationship between {beta}-cell function and glycated hemoglobin: results from the veterans administration genetic epidemiology study. Diabetes Care. 2011; 34(4):1006-10. PMC: 3064013. DOI: 10.2337/dc10-1352. View

Lebovitz H . Insulin resistance: definition and consequences. Exp Clin Endocrinol Diabetes. 2001; 109 Suppl 2:S135-48. DOI: 10.1055/s-2001-18576. View

Fernandez-Fernandez B, Sarafidis P, Kanbay M, Navarro-Gonzalez J, Soler M, Gorriz J . SGLT2 inhibitors for non-diabetic kidney disease: drugs to treat CKD that also improve glycaemia. Clin Kidney J. 2020; 13(5):728-733. PMC: 7577767. DOI: 10.1093/ckj/sfaa198. View

Abdul-Ghani M, DeFronzo R . Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract. 2008; 14(6):782-90. DOI: 10.4158/EP.14.6.782. View

Coelho M, Oliveira T, Fernandes R . Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013; 9(2):191-200. PMC: 3648822. DOI: 10.5114/aoms.2013.33181. View

Rampanelli E, Ochodnicky P, Vissers J, Butter L, Claessen N, Calcagni A . Excessive dietary lipid intake provokes an acquired form of lysosomal lipid storage disease in the kidney. J Pathol. 2018; 246(4):470-484. DOI: 10.1002/path.5150. View

Hudgel D, Patel S, Ahasic A, Bartlett S, Bessesen D, Coaker M . The Role of Weight Management in the Treatment of Adult Obstructive Sleep Apnea. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2018; 198(6):e70-e87. DOI: 10.1164/rccm.201807-1326ST. View

Li H, Chen Y, Tian X, Hong Y, Chen C, Sharokh N . Comparison of clinical characteristics between lean and obese nonalcoholic fatty liver disease in the northeast Chinese population. Arch Med Sci Atheroscler Dis. 2019; 4:e191-e195. PMC: 6749176. DOI: 10.5114/amsad.2019.87122. View

Lovejoy J, Bray G, Bourgeois M, Macchiavelli R, Rood J, Greeson C . Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women--a clinical research center study. J Clin Endocrinol Metab. 1996; 81(6):2198-203. DOI: 10.1210/jcem.81.6.8964851. View

10.

Mahfood Haddad T, Hamdeh S, Kanmanthareddy A, Alla V . Nonalcoholic fatty liver disease and the risk of clinical cardiovascular events: A systematic review and meta-analysis. Diabetes Metab Syndr. 2016; 11 Suppl 1:S209-S216. DOI: 10.1016/j.dsx.2016.12.033. View

11.

Papaetis G, Filippou P, Constantinidou K, Stylianou C . Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome. Clin Drug Investig. 2020; 40(8):695-713. DOI: 10.1007/s40261-020-00942-2. View

12.

Whited M, Olendzki E, Ma Y, Waring M, Schneider K, Appelhans B . Obstructive sleep apnea and weight loss treatment outcome among adults with metabolic syndrome. Health Psychol. 2016; 35(12):1316-1319. PMC: 5118132. DOI: 10.1037/hea0000379. View

13.

Veasey S, Rosen I . Obstructive Sleep Apnea in Adults. N Engl J Med. 2019; 380(15):1442-1449. DOI: 10.1056/NEJMcp1816152. View

14.

Tripathy P, Sahu A, Sahu M, Nagy A . Ultrasonographic evaluation of intra-abdominal fat distribution and study of its influence on subclinical atherosclerosis in women with polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol. 2017; 217:18-22. DOI: 10.1016/j.ejogrb.2017.08.011. View

15.

Abdel-Hamid A, Firgany A . Modulatory effect of empagliflozin on cellular parameters of endocrine pancreas in experimental pre-diabetes. Ann Anat. 2019; 224:153-160. DOI: 10.1016/j.aanat.2019.05.002. View

16.

Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R . Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016; 65(5):1190-5. DOI: 10.2337/db15-1356. View

17.

Al Jobori H, Daniele G, Adams J, Cersosimo E, Triplitt C, DeFronzo R . Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. Diabetes Obes Metab. 2017; 19(6):809-813. DOI: 10.1111/dom.12881. View

18.

Patoulias D . Sodium glucose co-transporter 2 inhibitors mediated ketogenesis in patients with metabolic syndrome: clear benefit or anticipated fear?. Arch Med Sci Atheroscler Dis. 2019; 4:e13-e15. PMC: 6451140. DOI: 10.5114/amsad.2019.83302. View

19.

Wagenknecht L, Langefeld C, Scherzinger A, Norris J, Haffner S, Saad M . Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study. Diabetes. 2003; 52(10):2490-6. DOI: 10.2337/diabetes.52.10.2490. View

20.

Papaetis G, Papakyriakou P, Panagiotou T . Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns. Arch Med Sci. 2015; 11(3):463-82. PMC: 4495144. DOI: 10.5114/aoms.2015.52350. View